Shares of CSL (ASX:CSL) fell almost 2% in recent trading on Thursday after Chairman Brian McNamee commented on the Australian government's efforts to avoid US tariffs on pharmaceuticals.
McNamee said that he doesn't think US President Donald Trump's demands are "unreasonable," and urged the government to make Australia's Pharmaceutical Benefits Scheme more efficient, The Australian reported Wednesday.
Australia could speed up the system for approvals and the mechanism for pricing of innovative new drugs, but this would "come at a cost," and the country would "need to make a contribution," he said.
Trump warned that the US could impose up to a 200% tariff on pharmaceuticals after a grace period of a year to 18 months.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。